EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Decentralized Clinical Trials in the Era of Real‐World Evidence: A Critical Assessment of Recent Experiences

Hongwei Wang iD, Nadia Daizadeh iD, Yuan-Li Shen iD, Jie Chen iD, Frank W Rockhold iD, Herbert Pang iD, Hana Lee iD

Clinical and Translational Science · 2025-09 · 18 (9)

DOI: 10.1111/cts.70328 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 08.09.2025. Verfasst von Hongwei Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Data and Statistical Sciences, AbbVie, North Chicago, Illinois, USA. Hauptthemen laut MEDLINE: COVID-19, Clinical Trials as Topic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the first decentralized clinical trial (DCT) was conducted in 2011, there has been an increased usage of DCT due to its benefits of patient‐centricity and generalizability of findings. This trend was further expedited by the global COVID‐19 pandemic. We identified 23 case studies across various therapeutic areas and grouped them into different categories according to their purposes—by necessity, for operational benefits, to address unique research questions, to validate innovative digital endpoints, or to validate decentralization as a clinical research platform. We leveraged the estimand framework from ICH E9(R1) including its five attributes (population, treatment, variable, intercurrent event, and summary measure) to critically assess their design and conduct. Common trends, opportunities, and challenges were reported along with recommendations for future DCT. Of note, intercurrent events and associated handling strategies are largely not present when reporting DCT. This is an area that can impact study conclusions and require more dedicated efforts when designing new DCTs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Clinical Trials as TopicHumansSARS-CoV-2Research DesignPandemics

Stichwörter der Autor:innen

case studydecentralized clinical trialdigital healthcare technologyestimand

Autor:innen und Institutionen

  • Data and Statistical Sciences, AbbVie, North Chicago, Illinois, USA.
  • Advanced Quantitative Sciences, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Food and Drug Administration, Silver Spring, Maryland, USA.
  • Taimei Intelligence Biopharma R&D, Shanghai, China.
  • Department of Biostatistics and Bioinformatics, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA.
  • PD Data Science and Analytics, Genentech, South San Francisco, California, USA.

ORCID-Profile: Hongwei Wang, Nadia Daizadeh, Yuan-Li Shen, Jie Chen, Frank W Rockhold, Herbert Pang, Hana Lee

Zitieren

APA

Wang, H., Daizadeh, N., Shen, Y. L., Chen, J., Rockhold, F. W., Pang, H., & Lee, H. (2025). Decentralized Clinical Trials in the Era of Real‐World Evidence: A Critical Assessment of Recent Experiences. Clinical and Translational Science, 18(9). https://doi.org/10.1111/cts.70328

Vancouver

Wang H, Daizadeh N, Shen YL, Chen J, Rockhold FW, Pang H, et al. Decentralized Clinical Trials in the Era of Real‐World Evidence: A Critical Assessment of Recent Experiences. Clinical and Translational Science. 2025;18(9). doi:10.1111/cts.70328

BibTeX
@article{Wang2025,
  author = {Wang, Hongwei and Daizadeh, Nadia and Shen, Yuan-Li and Chen, Jie and Rockhold, Frank W and Pang, Herbert and Lee, Hana},
  title = {Decentralized Clinical Trials in the Era of Real‐World Evidence: A Critical Assessment of Recent Experiences},
  journal = {Clinical and Translational Science},
  year = {2025},
  volume = {18},
  number = {9},
  doi = {10.1111/cts.70328}
}
Kostenlos starten →